| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft Rejection | 43 | 2023 | 4445 | 4.140 |
Why?
|
| Lymph Nodes | 24 | 2024 | 3466 | 4.140 |
Why?
|
| Graft Survival | 31 | 2024 | 3819 | 3.380 |
Why?
|
| Heart Transplantation | 27 | 2024 | 3233 | 3.050 |
Why?
|
| Serpins | 6 | 2020 | 247 | 2.150 |
Why?
|
| T-Lymphocytes, Regulatory | 20 | 2024 | 3080 | 1.940 |
Why?
|
| Rivers | 3 | 2021 | 64 | 1.890 |
Why?
|
| Islets of Langerhans Transplantation | 14 | 2024 | 740 | 1.870 |
Why?
|
| Dendritic Cells | 17 | 2019 | 2747 | 1.640 |
Why?
|
| Kidney Transplantation | 21 | 2023 | 4234 | 1.640 |
Why?
|
| Diabetes Mellitus, Type 1 | 19 | 2023 | 3415 | 1.480 |
Why?
|
| Thrombotic Microangiopathies | 3 | 2018 | 123 | 1.450 |
Why?
|
| Ecosystem | 3 | 2021 | 490 | 1.400 |
Why?
|
| Stromal Cells | 5 | 2022 | 1330 | 1.340 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 7 | 2020 | 499 | 1.320 |
Why?
|
| Reperfusion Injury | 4 | 2019 | 1023 | 1.300 |
Why?
|
| Mice, Inbred BALB C | 30 | 2024 | 6216 | 1.290 |
Why?
|
| Mesenchymal Stem Cells | 9 | 2020 | 1642 | 1.270 |
Why?
|
| Skin Transplantation | 5 | 2019 | 1083 | 1.250 |
Why?
|
| Kidney | 15 | 2023 | 7048 | 1.250 |
Why?
|
| Transplants | 2 | 2021 | 206 | 1.220 |
Why?
|
| Nanomedicine | 3 | 2023 | 290 | 1.220 |
Why?
|
| Mice, Inbred C57BL | 49 | 2024 | 22169 | 1.140 |
Why?
|
| Organ Transplantation | 5 | 2023 | 1157 | 1.130 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 2 | 2017 | 43 | 1.120 |
Why?
|
| Drug Delivery Systems | 6 | 2023 | 2226 | 1.060 |
Why?
|
| Nanoparticles | 8 | 2023 | 1959 | 1.060 |
Why?
|
| Immunologic Factors | 5 | 2019 | 1589 | 1.010 |
Why?
|
| Interleukin-6 | 5 | 2019 | 3208 | 1.010 |
Why?
|
| Kidney Diseases | 7 | 2023 | 2091 | 1.000 |
Why?
|
| Transplantation Tolerance | 6 | 2021 | 605 | 1.000 |
Why?
|
| Mice | 79 | 2024 | 81525 | 1.000 |
Why?
|
| Membrane Proteins | 8 | 2022 | 7856 | 0.980 |
Why?
|
| Animals | 105 | 2024 | 168459 | 0.960 |
Why?
|
| Tacrolimus | 3 | 2018 | 733 | 0.960 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2020 | 1351 | 0.930 |
Why?
|
| Fibroblasts | 5 | 2022 | 4141 | 0.930 |
Why?
|
| Drug Carriers | 2 | 2018 | 706 | 0.910 |
Why?
|
| Granzymes | 5 | 2020 | 277 | 0.870 |
Why?
|
| Mice, Inbred NOD | 15 | 2023 | 1827 | 0.860 |
Why?
|
| Renin-Angiotensin System | 4 | 2010 | 737 | 0.860 |
Why?
|
| CD4-Positive T-Lymphocytes | 8 | 2021 | 4369 | 0.810 |
Why?
|
| Endothelium, Lymphatic | 2 | 2020 | 63 | 0.800 |
Why?
|
| Immunosuppressive Agents | 15 | 2023 | 4174 | 0.800 |
Why?
|
| CD40 Ligand | 2 | 2022 | 522 | 0.800 |
Why?
|
| Mice, Knockout | 27 | 2024 | 14414 | 0.770 |
Why?
|
| T-Lymphocytes | 20 | 2024 | 10194 | 0.760 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2022 | 5671 | 0.740 |
Why?
|
| CD8-Positive T-Lymphocytes | 8 | 2024 | 4580 | 0.710 |
Why?
|
| Immunity | 4 | 2022 | 996 | 0.710 |
Why?
|
| Graft vs Host Disease | 6 | 2020 | 3029 | 0.710 |
Why?
|
| Receptors, Leptin | 1 | 2022 | 350 | 0.700 |
Why?
|
| Laminin | 4 | 2023 | 408 | 0.680 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2021 | 618 | 0.660 |
Why?
|
| Chemokines | 6 | 2023 | 960 | 0.650 |
Why?
|
| Glomerulonephritis | 2 | 2018 | 331 | 0.650 |
Why?
|
| Receptors, Chemokine | 5 | 2007 | 652 | 0.650 |
Why?
|
| Transplantation, Homologous | 19 | 2018 | 4806 | 0.650 |
Why?
|
| Pancreas | 4 | 2023 | 1691 | 0.640 |
Why?
|
| Tissue Donors | 8 | 2021 | 2331 | 0.630 |
Why?
|
| Venules | 3 | 2024 | 161 | 0.620 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2017 | 2865 | 0.610 |
Why?
|
| Fibrosis | 4 | 2021 | 2049 | 0.600 |
Why?
|
| Manipulation, Orthopedic | 2 | 2017 | 40 | 0.600 |
Why?
|
| Cold Ischemia | 1 | 2018 | 70 | 0.600 |
Why?
|
| Up-Regulation | 4 | 2019 | 4124 | 0.570 |
Why?
|
| Kidney Glomerulus | 5 | 2014 | 568 | 0.570 |
Why?
|
| Receptors, CCR5 | 4 | 2010 | 486 | 0.570 |
Why?
|
| Cell Movement | 8 | 2020 | 5203 | 0.570 |
Why?
|
| Bone Marrow Transplantation | 4 | 2016 | 2693 | 0.570 |
Why?
|
| Integrin beta3 | 2 | 2007 | 120 | 0.560 |
Why?
|
| Tenotomy | 1 | 2017 | 55 | 0.550 |
Why?
|
| Serine Endopeptidases | 2 | 2013 | 1022 | 0.550 |
Why?
|
| Inflammation | 13 | 2023 | 10773 | 0.550 |
Why?
|
| Disease Models, Animal | 18 | 2021 | 18252 | 0.540 |
Why?
|
| Casts, Surgical | 2 | 2017 | 183 | 0.540 |
Why?
|
| Acute Kidney Injury | 2 | 2019 | 1924 | 0.530 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2018 | 694 | 0.520 |
Why?
|
| Orthotic Devices | 1 | 2017 | 129 | 0.520 |
Why?
|
| OX40 Ligand | 1 | 2015 | 55 | 0.510 |
Why?
|
| Cytokines | 14 | 2023 | 7396 | 0.500 |
Why?
|
| Water Movements | 1 | 2015 | 17 | 0.500 |
Why?
|
| Membrane Glycoproteins | 3 | 2021 | 3702 | 0.490 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2018 | 373 | 0.490 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2010 | 1119 | 0.480 |
Why?
|
| Podocytes | 1 | 2019 | 405 | 0.480 |
Why?
|
| Hematologic Neoplasms | 2 | 2018 | 1896 | 0.480 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2018 | 481 | 0.470 |
Why?
|
| NF-kappa B | 5 | 2024 | 2490 | 0.460 |
Why?
|
| Quinoxalines | 2 | 2017 | 296 | 0.460 |
Why?
|
| Lymphocyte Activation | 7 | 2021 | 5486 | 0.460 |
Why?
|
| Angiotensin II | 3 | 2009 | 849 | 0.460 |
Why?
|
| Fluorocarbons | 1 | 2019 | 492 | 0.460 |
Why?
|
| Polymorphism, Genetic | 5 | 2012 | 4243 | 0.450 |
Why?
|
| Lymphotoxin beta Receptor | 3 | 2024 | 25 | 0.450 |
Why?
|
| STAT1 Transcription Factor | 1 | 2015 | 341 | 0.450 |
Why?
|
| Receptors, CCR2 | 4 | 2008 | 215 | 0.440 |
Why?
|
| Biocompatible Materials | 2 | 2019 | 1685 | 0.440 |
Why?
|
| Insulin-Secreting Cells | 3 | 2022 | 901 | 0.440 |
Why?
|
| Iran | 6 | 2015 | 737 | 0.430 |
Why?
|
| Thiazolidinediones | 2 | 2017 | 461 | 0.430 |
Why?
|
| Transplantation Conditioning | 2 | 2018 | 1590 | 0.430 |
Why?
|
| Polyesters | 2 | 2016 | 373 | 0.420 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 2471 | 0.420 |
Why?
|
| Clubfoot | 3 | 2020 | 87 | 0.420 |
Why?
|
| Lymphotoxin-alpha | 2 | 2024 | 93 | 0.400 |
Why?
|
| Chemokine CXCL12 | 3 | 2024 | 454 | 0.380 |
Why?
|
| Immunologic Memory | 2 | 2015 | 1359 | 0.370 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 1496 | 0.370 |
Why?
|
| Hydrogels | 3 | 2024 | 720 | 0.360 |
Why?
|
| Homozygote | 1 | 2015 | 1776 | 0.360 |
Why?
|
| Mineral Oil | 1 | 2010 | 21 | 0.350 |
Why?
|
| Humans | 102 | 2024 | 761504 | 0.350 |
Why?
|
| Students, Nursing | 1 | 2010 | 46 | 0.350 |
Why?
|
| Macrophage Activation | 1 | 2013 | 553 | 0.350 |
Why?
|
| Mentally Ill Persons | 1 | 2011 | 128 | 0.350 |
Why?
|
| Tissue and Organ Procurement | 1 | 2018 | 961 | 0.350 |
Why?
|
| Los Angeles | 2 | 2021 | 243 | 0.340 |
Why?
|
| Receptors, Nicotinic | 1 | 2013 | 495 | 0.340 |
Why?
|
| Community-Based Participatory Research | 1 | 2012 | 221 | 0.340 |
Why?
|
| Object Attachment | 1 | 2012 | 326 | 0.340 |
Why?
|
| Cerebral Arteries | 1 | 2012 | 490 | 0.330 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2010 | 629 | 0.330 |
Why?
|
| Neoplasms | 7 | 2022 | 22170 | 0.330 |
Why?
|
| Urban Health | 1 | 2012 | 532 | 0.330 |
Why?
|
| Flow Cytometry | 8 | 2021 | 5869 | 0.330 |
Why?
|
| Child of Impaired Parents | 1 | 2012 | 460 | 0.320 |
Why?
|
| Mice, Transgenic | 10 | 2022 | 9539 | 0.320 |
Why?
|
| Homeostasis | 3 | 2022 | 3323 | 0.310 |
Why?
|
| Neovascularization, Pathologic | 1 | 2018 | 2645 | 0.300 |
Why?
|
| Blood Flow Velocity | 1 | 2012 | 1371 | 0.300 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2023 | 974 | 0.300 |
Why?
|
| Interferon-gamma | 5 | 2023 | 3162 | 0.300 |
Why?
|
| Immunotherapy | 3 | 2023 | 4652 | 0.300 |
Why?
|
| Parent-Child Relations | 1 | 2012 | 761 | 0.300 |
Why?
|
| Hyperglycemia | 5 | 2022 | 1376 | 0.300 |
Why?
|
| Lymphatic Vessels | 3 | 2022 | 358 | 0.290 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2015 | 1784 | 0.290 |
Why?
|
| Cyclosporine | 1 | 2010 | 778 | 0.290 |
Why?
|
| Selectins | 1 | 2007 | 101 | 0.290 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 1727 | 0.290 |
Why?
|
| Endothelial Cells | 4 | 2024 | 3548 | 0.290 |
Why?
|
| Gene Targeting | 1 | 2010 | 838 | 0.280 |
Why?
|
| Nursing Staff, Hospital | 1 | 2010 | 348 | 0.280 |
Why?
|
| Immune Evasion | 1 | 2010 | 363 | 0.280 |
Why?
|
| Killer Cells, Natural | 4 | 2011 | 2200 | 0.280 |
Why?
|
| Signal Transduction | 13 | 2024 | 23445 | 0.280 |
Why?
|
| Receptors, CXCR4 | 2 | 2010 | 727 | 0.270 |
Why?
|
| Th2 Cells | 5 | 2018 | 1060 | 0.270 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2010 | 579 | 0.270 |
Why?
|
| Ischemia | 2 | 2017 | 1882 | 0.260 |
Why?
|
| Cell Differentiation | 6 | 2023 | 11528 | 0.260 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 3 | 2021 | 306 | 0.260 |
Why?
|
| Chemokines, CC | 1 | 2007 | 283 | 0.260 |
Why?
|
| Needs Assessment | 1 | 2012 | 1139 | 0.260 |
Why?
|
| Male | 51 | 2024 | 360804 | 0.260 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 1250 | 0.260 |
Why?
|
| Receptors, Purinergic P2X7 | 2 | 2018 | 85 | 0.250 |
Why?
|
| Immunomodulation | 2 | 2019 | 549 | 0.250 |
Why?
|
| Oxidative Stress | 2 | 2014 | 3113 | 0.250 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 2 | 1999 | 335 | 0.250 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2015 | 1809 | 0.250 |
Why?
|
| Complement System Proteins | 2 | 2021 | 736 | 0.240 |
Why?
|
| Lumbosacral Region | 1 | 2006 | 293 | 0.240 |
Why?
|
| Islets of Langerhans | 4 | 2022 | 1341 | 0.240 |
Why?
|
| Microspheres | 2 | 2019 | 784 | 0.240 |
Why?
|
| Sacrum | 1 | 2006 | 276 | 0.240 |
Why?
|
| Interprofessional Relations | 1 | 2010 | 990 | 0.230 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2004 | 47 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 5 | 2017 | 9177 | 0.230 |
Why?
|
| Female | 46 | 2022 | 392644 | 0.230 |
Why?
|
| Gene Expression Regulation | 7 | 2022 | 11903 | 0.230 |
Why?
|
| Silk | 1 | 2024 | 90 | 0.220 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2020 | 347 | 0.220 |
Why?
|
| Child Abuse | 1 | 2012 | 1077 | 0.220 |
Why?
|
| Ultrasonography | 1 | 2017 | 5972 | 0.220 |
Why?
|
| Haplotypes | 1 | 2010 | 2713 | 0.220 |
Why?
|
| Nephrectomy | 2 | 2012 | 937 | 0.220 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 2176 | 0.220 |
Why?
|
| Sirolimus | 2 | 2022 | 1533 | 0.220 |
Why?
|
| Peptides | 2 | 2017 | 4358 | 0.210 |
Why?
|
| Bone Marrow Cells | 5 | 2015 | 2416 | 0.210 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2019 | 2469 | 0.210 |
Why?
|
| Cell Proliferation | 7 | 2020 | 10445 | 0.210 |
Why?
|
| Urban Population | 1 | 2011 | 2036 | 0.210 |
Why?
|
| Reticulin | 1 | 2022 | 19 | 0.210 |
Why?
|
| Antioxidants | 1 | 2010 | 1668 | 0.210 |
Why?
|
| Interleukin-10 | 3 | 2018 | 1175 | 0.210 |
Why?
|
| Transendothelial and Transepithelial Migration | 2 | 2020 | 100 | 0.210 |
Why?
|
| Extracellular Matrix | 2 | 2022 | 1726 | 0.210 |
Why?
|
| Autoimmunity | 3 | 2021 | 1356 | 0.200 |
Why?
|
| Renal Dialysis | 1 | 2012 | 1797 | 0.200 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2017 | 899 | 0.200 |
Why?
|
| Immune Tolerance | 4 | 2021 | 2303 | 0.200 |
Why?
|
| Macrophages | 4 | 2021 | 5769 | 0.200 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2022 | 50 | 0.200 |
Why?
|
| Tissue Adhesives | 2 | 2024 | 173 | 0.200 |
Why?
|
| Time Factors | 15 | 2019 | 39967 | 0.190 |
Why?
|
| Mental Disorders | 2 | 2012 | 6845 | 0.190 |
Why?
|
| Taurodeoxycholic Acid | 1 | 2021 | 13 | 0.190 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2021 | 127 | 0.190 |
Why?
|
| Mice, Inbred DBA | 4 | 2021 | 621 | 0.190 |
Why?
|
| Cell Survival | 3 | 2017 | 5791 | 0.190 |
Why?
|
| Melanoma, Experimental | 1 | 2024 | 560 | 0.190 |
Why?
|
| Cell Line, Tumor | 6 | 2024 | 16981 | 0.190 |
Why?
|
| Spleen | 3 | 2018 | 2295 | 0.190 |
Why?
|
| Angiotensins | 1 | 2001 | 143 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5368 | 0.180 |
Why?
|
| Angioedema | 1 | 2002 | 184 | 0.180 |
Why?
|
| STAT5 Transcription Factor | 1 | 2021 | 265 | 0.180 |
Why?
|
| Cell Line | 5 | 2022 | 15601 | 0.180 |
Why?
|
| Organoids | 2 | 2024 | 740 | 0.180 |
Why?
|
| Antigens, CD | 3 | 2018 | 4003 | 0.180 |
Why?
|
| Equinus Deformity | 1 | 2020 | 6 | 0.180 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2022 | 416 | 0.170 |
Why?
|
| Gene Knockdown Techniques | 2 | 2017 | 1612 | 0.170 |
Why?
|
| Ureteral Obstruction | 1 | 2021 | 293 | 0.170 |
Why?
|
| Fetal Macrosomia | 1 | 2020 | 141 | 0.170 |
Why?
|
| Valine | 1 | 2021 | 408 | 0.170 |
Why?
|
| Sarcoma, Kaposi | 1 | 2002 | 374 | 0.170 |
Why?
|
| Adult | 28 | 2022 | 221177 | 0.170 |
Why?
|
| HLA Antigens | 2 | 2015 | 1328 | 0.160 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2022 | 2155 | 0.160 |
Why?
|
| Endothelium | 1 | 2022 | 765 | 0.160 |
Why?
|
| Blood Coagulation Disorders | 1 | 2022 | 350 | 0.160 |
Why?
|
| Platelet Count | 1 | 2021 | 781 | 0.160 |
Why?
|
| Methacrylates | 1 | 2019 | 109 | 0.160 |
Why?
|
| Talus | 1 | 2020 | 86 | 0.160 |
Why?
|
| Injections, Intraperitoneal | 3 | 2021 | 413 | 0.160 |
Why?
|
| Chemokine CCL21 | 3 | 2020 | 50 | 0.160 |
Why?
|
| Interleukin-4 | 4 | 2017 | 1149 | 0.160 |
Why?
|
| Ankle Joint | 2 | 2020 | 446 | 0.150 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2002 | 328 | 0.150 |
Why?
|
| Cells, Cultured | 7 | 2022 | 18965 | 0.150 |
Why?
|
| Organ Preservation | 1 | 2021 | 382 | 0.150 |
Why?
|
| Integrin alpha Chains | 1 | 2018 | 95 | 0.150 |
Why?
|
| Coronavirus | 1 | 2020 | 154 | 0.150 |
Why?
|
| Lupus Nephritis | 1 | 2021 | 316 | 0.150 |
Why?
|
| Isoantibodies | 2 | 2014 | 674 | 0.150 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 1036 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2021 | 3810 | 0.150 |
Why?
|
| Integrin alpha2beta1 | 1 | 2017 | 17 | 0.150 |
Why?
|
| Oxides | 1 | 2019 | 401 | 0.150 |
Why?
|
| Transplantation, Heterotopic | 1 | 2018 | 174 | 0.150 |
Why?
|
| Gene Deletion | 2 | 2020 | 2665 | 0.150 |
Why?
|
| Health Status | 1 | 2011 | 4077 | 0.150 |
Why?
|
| Ferric Compounds | 1 | 2019 | 378 | 0.150 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 242 | 0.140 |
Why?
|
| Gelatin | 1 | 2019 | 220 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2003 | 809 | 0.140 |
Why?
|
| New York City | 1 | 2020 | 731 | 0.140 |
Why?
|
| Megakaryocytes | 1 | 2021 | 566 | 0.140 |
Why?
|
| Hormones | 1 | 2021 | 869 | 0.140 |
Why?
|
| Mycophenolic Acid | 1 | 2019 | 348 | 0.140 |
Why?
|
| Transplantation Immunology | 2 | 2022 | 532 | 0.140 |
Why?
|
| Glioblastoma | 2 | 2023 | 3482 | 0.140 |
Why?
|
| Middle Aged | 24 | 2022 | 220895 | 0.140 |
Why?
|
| Immunophenotyping | 2 | 2019 | 1870 | 0.140 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2010 | 662 | 0.140 |
Why?
|
| Herpesvirus 1, Human | 1 | 2023 | 753 | 0.140 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2002 | 560 | 0.140 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 3877 | 0.140 |
Why?
|
| STAT3 Transcription Factor | 3 | 2018 | 871 | 0.140 |
Why?
|
| Lumbar Vertebrae | 1 | 2006 | 1879 | 0.140 |
Why?
|
| Perfusion | 1 | 2021 | 1373 | 0.140 |
Why?
|
| Mammals | 1 | 2022 | 1132 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 3889 | 0.140 |
Why?
|
| Mucin-1 | 1 | 2021 | 540 | 0.140 |
Why?
|
| Creatinine | 2 | 2019 | 1899 | 0.130 |
Why?
|
| Mental Health | 1 | 2011 | 3250 | 0.130 |
Why?
|
| Gastrectomy | 1 | 2021 | 672 | 0.130 |
Why?
|
| Th17 Cells | 3 | 2018 | 794 | 0.130 |
Why?
|
| Braces | 1 | 2017 | 138 | 0.130 |
Why?
|
| Kidney Function Tests | 1 | 1998 | 678 | 0.130 |
Why?
|
| Virus Diseases | 1 | 2022 | 718 | 0.130 |
Why?
|
| Replantation | 1 | 2017 | 145 | 0.130 |
Why?
|
| Reperfusion | 1 | 2017 | 271 | 0.130 |
Why?
|
| Oncogene Proteins v-myb | 1 | 2015 | 25 | 0.130 |
Why?
|
| Amputation, Traumatic | 1 | 2017 | 135 | 0.130 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2002 | 1039 | 0.130 |
Why?
|
| Receptors, CXCR3 | 2 | 2007 | 238 | 0.130 |
Why?
|
| Skin Ulcer | 1 | 2017 | 130 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 1516 | 0.130 |
Why?
|
| Capillaries | 1 | 2018 | 755 | 0.120 |
Why?
|
| Receptors, Interleukin-2 | 2 | 2020 | 562 | 0.120 |
Why?
|
| Premedication | 1 | 2016 | 246 | 0.120 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2018 | 1435 | 0.120 |
Why?
|
| Small Molecule Libraries | 1 | 2020 | 733 | 0.120 |
Why?
|
| Cancer Vaccines | 1 | 2023 | 1051 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 15936 | 0.120 |
Why?
|
| Immunoglobulins | 1 | 2018 | 853 | 0.120 |
Why?
|
| Polysaccharides | 1 | 2021 | 1014 | 0.120 |
Why?
|
| Contrast Media | 2 | 2019 | 5311 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 1089 | 0.120 |
Why?
|
| Mice, SCID | 4 | 2014 | 2626 | 0.120 |
Why?
|
| Fucosyltransferases | 1 | 2015 | 117 | 0.120 |
Why?
|
| Histocompatibility Testing | 3 | 2007 | 712 | 0.120 |
Why?
|
| Bartter Syndrome | 1 | 1994 | 23 | 0.120 |
Why?
|
| Fucose | 1 | 2015 | 122 | 0.120 |
Why?
|
| Biopsy | 4 | 2019 | 6766 | 0.120 |
Why?
|
| Adolescent | 10 | 2021 | 88319 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2022 | 2612 | 0.120 |
Why?
|
| Skin Diseases | 1 | 2003 | 1094 | 0.120 |
Why?
|
| Temperature | 1 | 2021 | 2226 | 0.120 |
Why?
|
| Wound Healing | 2 | 2019 | 2805 | 0.120 |
Why?
|
| Fractures, Bone | 1 | 2006 | 2046 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2014 | 2455 | 0.120 |
Why?
|
| Metabolome | 1 | 2021 | 989 | 0.120 |
Why?
|
| Oxygen | 2 | 2024 | 4227 | 0.110 |
Why?
|
| MicroRNAs | 2 | 2021 | 3816 | 0.110 |
Why?
|
| Antibodies | 2 | 2016 | 2418 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2012 | 12059 | 0.110 |
Why?
|
| Complement Activation | 1 | 2016 | 445 | 0.110 |
Why?
|
| Swine | 3 | 2019 | 5915 | 0.110 |
Why?
|
| Young Adult | 8 | 2018 | 59243 | 0.110 |
Why?
|
| Congresses as Topic | 1 | 2018 | 803 | 0.110 |
Why?
|
| B-Lymphocytes | 3 | 2015 | 4758 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2022 | 4575 | 0.110 |
Why?
|
| Umbilical Cord | 1 | 2014 | 177 | 0.110 |
Why?
|
| Th1 Cells | 4 | 2012 | 1036 | 0.110 |
Why?
|
| Motion | 1 | 2017 | 779 | 0.110 |
Why?
|
| Histocompatibility | 1 | 2014 | 317 | 0.110 |
Why?
|
| Biological Transport, Active | 1 | 2013 | 328 | 0.110 |
Why?
|
| Purinergic P2X Receptor Antagonists | 1 | 2012 | 24 | 0.110 |
Why?
|
| Apoptosis | 3 | 2020 | 9486 | 0.110 |
Why?
|
| Exosomes | 1 | 2017 | 424 | 0.110 |
Why?
|
| Endothelium, Vascular | 2 | 2016 | 4431 | 0.110 |
Why?
|
| E-Selectin | 1 | 2015 | 576 | 0.100 |
Why?
|
| Treatment Outcome | 7 | 2018 | 64680 | 0.100 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2015 | 293 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3084 | 0.100 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3204 | 0.100 |
Why?
|
| Niacin | 1 | 2013 | 118 | 0.100 |
Why?
|
| ROC Curve | 2 | 2018 | 3579 | 0.100 |
Why?
|
| Discriminant Analysis | 1 | 2012 | 222 | 0.100 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 6814 | 0.100 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 2016 | 0.100 |
Why?
|
| Ligands | 3 | 2019 | 3272 | 0.100 |
Why?
|
| Immediate-Early Proteins | 1 | 2015 | 449 | 0.100 |
Why?
|
| History, 17th Century | 1 | 2012 | 108 | 0.100 |
Why?
|
| Antigens, Surface | 1 | 2016 | 1606 | 0.100 |
Why?
|
| Hypothermia, Induced | 1 | 2017 | 753 | 0.100 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 11076 | 0.100 |
Why?
|
| History, Ancient | 1 | 2012 | 212 | 0.100 |
Why?
|
| Health Surveys | 2 | 2012 | 4061 | 0.100 |
Why?
|
| Extremities | 1 | 2017 | 867 | 0.100 |
Why?
|
| Fishes | 1 | 2015 | 603 | 0.100 |
Why?
|
| Microscopy, Confocal | 2 | 2017 | 1971 | 0.090 |
Why?
|
| Biosensing Techniques | 1 | 2017 | 650 | 0.090 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 992 | 0.090 |
Why?
|
| Paclitaxel | 1 | 2018 | 1732 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2017 | 1802 | 0.090 |
Why?
|
| Antipyrine | 1 | 2010 | 40 | 0.090 |
Why?
|
| Models, Animal | 1 | 2017 | 2112 | 0.090 |
Why?
|
| Iron | 1 | 2019 | 1793 | 0.090 |
Why?
|
| Diabetes, Gestational | 1 | 2020 | 1248 | 0.090 |
Why?
|
| Proteome | 1 | 2020 | 1862 | 0.090 |
Why?
|
| Hematocrit | 1 | 2012 | 623 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2019 | 2242 | 0.090 |
Why?
|
| Age Factors | 4 | 2021 | 18395 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 3602 | 0.090 |
Why?
|
| Chemotaxis | 1 | 2013 | 598 | 0.090 |
Why?
|
| Infant | 5 | 2021 | 36192 | 0.090 |
Why?
|
| Autoantigens | 2 | 2014 | 891 | 0.090 |
Why?
|
| Lipoproteins, LDL | 1 | 2013 | 642 | 0.090 |
Why?
|
| Lung Injury | 1 | 2014 | 422 | 0.090 |
Why?
|
| Stress, Mechanical | 1 | 2015 | 1674 | 0.090 |
Why?
|
| Free Radical Scavengers | 1 | 2010 | 211 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2020 | 10766 | 0.090 |
Why?
|
| Transcription Factors | 3 | 2024 | 12128 | 0.080 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 263 | 0.080 |
Why?
|
| Aged | 12 | 2023 | 169289 | 0.080 |
Why?
|
| Apolipoproteins | 1 | 2012 | 326 | 0.080 |
Why?
|
| Benzylamines | 1 | 2010 | 247 | 0.080 |
Why?
|
| Lipopolysaccharides | 2 | 2017 | 2206 | 0.080 |
Why?
|
| Urea | 1 | 2012 | 443 | 0.080 |
Why?
|
| Heterocyclic Compounds | 1 | 2010 | 246 | 0.080 |
Why?
|
| Child | 8 | 2021 | 80153 | 0.080 |
Why?
|
| Acute Disease | 3 | 2007 | 7237 | 0.080 |
Why?
|
| Isoantigens | 2 | 2012 | 551 | 0.080 |
Why?
|
| History, 19th Century | 1 | 2012 | 720 | 0.080 |
Why?
|
| Stem Cells | 2 | 2014 | 3522 | 0.080 |
Why?
|
| NFATC Transcription Factors | 1 | 2011 | 389 | 0.080 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2010 | 175 | 0.080 |
Why?
|
| BK Virus | 1 | 2010 | 123 | 0.080 |
Why?
|
| Receptors, Interleukin-8A | 1 | 2009 | 46 | 0.080 |
Why?
|
| Lymphoid Tissue | 1 | 2010 | 445 | 0.080 |
Why?
|
| Mitochondrial Proteins | 1 | 2015 | 976 | 0.080 |
Why?
|
| Nephritis, Interstitial | 1 | 2010 | 155 | 0.080 |
Why?
|
| Interleukin-17 | 1 | 2015 | 912 | 0.080 |
Why?
|
| Postoperative Period | 3 | 2003 | 1813 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2018 | 2416 | 0.080 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 1897 | 0.080 |
Why?
|
| Vascular Resistance | 1 | 2012 | 930 | 0.080 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2015 | 509 | 0.080 |
Why?
|
| Desensitization, Immunologic | 1 | 2014 | 556 | 0.080 |
Why?
|
| Interleukins | 1 | 2013 | 782 | 0.080 |
Why?
|
| Disease Progression | 3 | 2020 | 13506 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 999 | 0.080 |
Why?
|
| HLA-D Antigens | 1 | 2008 | 129 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 5796 | 0.080 |
Why?
|
| Primary Graft Dysfunction | 1 | 2009 | 111 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2010 | 307 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 1 | 2018 | 1943 | 0.080 |
Why?
|
| Immunity, Innate | 2 | 2023 | 3065 | 0.080 |
Why?
|
| Polyomavirus Infections | 1 | 2010 | 194 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2015 | 2919 | 0.070 |
Why?
|
| Risk Factors | 5 | 2018 | 74206 | 0.070 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2009 | 362 | 0.070 |
Why?
|
| Lipoproteins, HDL | 1 | 2012 | 676 | 0.070 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2007 | 60 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2811 | 0.070 |
Why?
|
| Diabetic Nephropathies | 1 | 2014 | 973 | 0.070 |
Why?
|
| Postoperative Complications | 3 | 2007 | 15631 | 0.070 |
Why?
|
| Protein Binding | 2 | 2019 | 9351 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2002 | 4026 | 0.070 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 39106 | 0.070 |
Why?
|
| Integrin alpha4beta1 | 1 | 2007 | 119 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2019 | 2547 | 0.070 |
Why?
|
| Mitochondria | 2 | 2022 | 3624 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2021 | 6391 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2017 | 2690 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2003 | 4249 | 0.070 |
Why?
|
| Adenosine Triphosphate | 1 | 2012 | 1989 | 0.070 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 153 | 0.070 |
Why?
|
| Focus Groups | 1 | 2012 | 1413 | 0.070 |
Why?
|
| Coculture Techniques | 1 | 2010 | 1341 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2015 | 22176 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2012 | 1525 | 0.060 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 5840 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2011 | 2281 | 0.060 |
Why?
|
| Cell Separation | 1 | 2011 | 1720 | 0.060 |
Why?
|
| Child, Preschool | 5 | 2021 | 42230 | 0.060 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 3429 | 0.060 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2007 | 377 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 1600 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2018 | 10090 | 0.060 |
Why?
|
| Lymphotoxin alpha1, beta2 Heterotrimer | 1 | 2024 | 4 | 0.060 |
Why?
|
| Reference Values | 2 | 2006 | 4920 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 9420 | 0.060 |
Why?
|
| Aging | 3 | 2023 | 8708 | 0.060 |
Why?
|
| Prevalence | 2 | 2012 | 15732 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 12148 | 0.060 |
Why?
|
| Recurrence | 1 | 2017 | 8465 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2012 | 2696 | 0.060 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2004 | 57 | 0.060 |
Why?
|
| Retrospective Studies | 7 | 2020 | 80636 | 0.060 |
Why?
|
| Incidence | 2 | 2018 | 21353 | 0.060 |
Why?
|
| Hypertension, Renal | 1 | 2004 | 135 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2012 | 2767 | 0.060 |
Why?
|
| Pandemics | 2 | 2020 | 8654 | 0.060 |
Why?
|
| L-Selectin | 1 | 2004 | 209 | 0.050 |
Why?
|
| Cell Division | 2 | 2010 | 4465 | 0.050 |
Why?
|
| Mutation | 2 | 2018 | 30052 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 2065 | 0.050 |
Why?
|
| C-Peptide | 2 | 2020 | 440 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2024 | 11460 | 0.050 |
Why?
|
| Genotype | 3 | 2012 | 12990 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2002 | 5821 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2007 | 1529 | 0.050 |
Why?
|
| Immunoconjugates | 1 | 2010 | 954 | 0.050 |
Why?
|
| Focal Adhesions | 1 | 2023 | 115 | 0.050 |
Why?
|
| Prediabetic State | 1 | 2008 | 545 | 0.050 |
Why?
|
| Transplantation, Isogeneic | 1 | 2002 | 248 | 0.050 |
Why?
|
| Proinsulin | 1 | 2022 | 135 | 0.050 |
Why?
|
| Adoptive Transfer | 2 | 2019 | 819 | 0.050 |
Why?
|
| Registries | 1 | 2018 | 8224 | 0.050 |
Why?
|
| Rats, Nude | 1 | 2021 | 105 | 0.050 |
Why?
|
| Melanoma | 1 | 2020 | 5709 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 1135 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 4352 | 0.050 |
Why?
|
| Sialyltransferases | 1 | 2021 | 83 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2010 | 26125 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2022 | 184 | 0.050 |
Why?
|
| Coronary Stenosis | 1 | 2007 | 794 | 0.050 |
Why?
|
| Engineering | 1 | 2021 | 56 | 0.050 |
Why?
|
| Infant, Newborn | 3 | 2020 | 26198 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2012 | 4159 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2007 | 1600 | 0.050 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2021 | 138 | 0.050 |
Why?
|
| Hypertension | 1 | 2001 | 8540 | 0.050 |
Why?
|
| Survival Rate | 1 | 2015 | 12725 | 0.050 |
Why?
|
| Cytochromes c | 1 | 2021 | 173 | 0.050 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 4 | 1 | 2021 | 73 | 0.050 |
Why?
|
| Injections | 1 | 2024 | 830 | 0.050 |
Why?
|
| Cardiotonic Agents | 1 | 2024 | 539 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15842 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 1886 | 0.050 |
Why?
|
| Germinal Center | 1 | 2023 | 380 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2012 | 8320 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2022 | 9031 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 1626 | 0.050 |
Why?
|
| Pharyngitis | 1 | 2002 | 219 | 0.050 |
Why?
|
| Losartan | 1 | 2002 | 265 | 0.050 |
Why?
|
| Autoimmune Diseases | 2 | 2003 | 2244 | 0.040 |
Why?
|
| Integrin alpha6 | 1 | 2020 | 30 | 0.040 |
Why?
|
| Enalapril | 1 | 2002 | 312 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2021 | 613 | 0.040 |
Why?
|
| Probability | 1 | 2006 | 2477 | 0.040 |
Why?
|
| Dystroglycans | 1 | 2020 | 62 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2021 | 420 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2011 | 2598 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2007 | 3087 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2002 | 17904 | 0.040 |
Why?
|
| Chemokine CCL19 | 1 | 2019 | 35 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2023 | 606 | 0.040 |
Why?
|
| Immunoprecipitation | 1 | 2021 | 878 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2021 | 41487 | 0.040 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 1999 | 40 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 6534 | 0.040 |
Why?
|
| Bioreactors | 1 | 2020 | 247 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2004 | 1967 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2003 | 1055 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2022 | 1646 | 0.040 |
Why?
|
| Italy | 1 | 2020 | 842 | 0.040 |
Why?
|
| Cough | 1 | 2002 | 594 | 0.040 |
Why?
|
| Immunization | 1 | 2023 | 1228 | 0.040 |
Why?
|
| Basement Membrane | 1 | 1999 | 349 | 0.040 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2018 | 150 | 0.040 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 1999 | 88 | 0.040 |
Why?
|
| Psychotic Disorders | 1 | 2013 | 3223 | 0.040 |
Why?
|
| Vinculin | 1 | 2017 | 59 | 0.040 |
Why?
|
| Anxiety | 1 | 2012 | 4573 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2010 | 3060 | 0.040 |
Why?
|
| Cell Communication | 1 | 2024 | 1657 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2019 | 945 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2020 | 691 | 0.040 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2017 | 120 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2006 | 6228 | 0.040 |
Why?
|
| Mannose-Binding Lectins | 1 | 2017 | 96 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 7827 | 0.030 |
Why?
|
| Compressive Strength | 1 | 2017 | 158 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2024 | 2915 | 0.030 |
Why?
|
| Rats | 2 | 2024 | 23742 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2021 | 1834 | 0.030 |
Why?
|
| RNA | 1 | 2006 | 2726 | 0.030 |
Why?
|
| Hyaluronic Acid | 1 | 2019 | 483 | 0.030 |
Why?
|
| Joint Capsule | 1 | 2016 | 68 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13639 | 0.030 |
Why?
|
| Proteomics | 2 | 2020 | 3849 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2017 | 731 | 0.030 |
Why?
|
| Myocytes, Cardiac | 1 | 2024 | 1668 | 0.030 |
Why?
|
| Cadherins | 1 | 2020 | 903 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 2014 | 2561 | 0.030 |
Why?
|
| Mass Screening | 1 | 2011 | 5428 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2023 | 2116 | 0.030 |
Why?
|
| Tendon Transfer | 1 | 2016 | 124 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2015 | 201 | 0.030 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2015 | 139 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2019 | 726 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2015 | 915 | 0.030 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2015 | 177 | 0.030 |
Why?
|
| Dermis | 1 | 2015 | 202 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 585 | 0.030 |
Why?
|
| Cell Polarity | 1 | 2017 | 637 | 0.030 |
Why?
|
| Estradiol | 1 | 2021 | 1937 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2021 | 1961 | 0.030 |
Why?
|
| Indomethacin | 1 | 1994 | 325 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1092 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 2020 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 2014 | 206 | 0.030 |
Why?
|
| Achilles Tendon | 1 | 2016 | 180 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 21012 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2014 | 477 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2020 | 1889 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2015 | 496 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 1486 | 0.030 |
Why?
|
| Depression | 1 | 2012 | 8124 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2002 | 2024 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1787 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2013 | 243 | 0.030 |
Why?
|
| Hyperoxia | 1 | 2014 | 258 | 0.030 |
Why?
|
| Immunocompetence | 1 | 2012 | 138 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 12690 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 2017 | 1170 | 0.030 |
Why?
|
| Proteins | 1 | 2007 | 6032 | 0.030 |
Why?
|
| HLA-DR4 Antigen | 1 | 2011 | 22 | 0.020 |
Why?
|
| Insulin Resistance | 2 | 2021 | 3963 | 0.020 |
Why?
|
| Histocompatibility Antigens | 1 | 2013 | 464 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2020 | 1396 | 0.020 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2014 | 326 | 0.020 |
Why?
|
| Genes, MHC Class II | 1 | 2011 | 434 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 14666 | 0.020 |
Why?
|
| United States | 1 | 2018 | 72334 | 0.020 |
Why?
|
| Phenotype | 1 | 2008 | 16591 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 1749 | 0.020 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 1860 | 0.020 |
Why?
|
| DNA | 1 | 2023 | 7212 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 664 | 0.020 |
Why?
|
| Living Donors | 1 | 2014 | 641 | 0.020 |
Why?
|
| Computational Biology | 1 | 2021 | 3518 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2021 | 3673 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2010 | 225 | 0.020 |
Why?
|
| Boston | 2 | 2014 | 9326 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2014 | 2115 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 1334 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2014 | 2678 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2015 | 1560 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2019 | 3769 | 0.020 |
Why?
|
| Radiography | 1 | 2020 | 6965 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 4915 | 0.020 |
Why?
|
| Antilymphocyte Serum | 1 | 2010 | 487 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2010 | 677 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 2822 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2007 | 103 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 2538 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2018 | 2986 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2007 | 216 | 0.020 |
Why?
|
| Viremia | 1 | 2010 | 707 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 2141 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 891 | 0.020 |
Why?
|
| Communicable Diseases | 1 | 2014 | 875 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2001 | 8481 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2014 | 2555 | 0.020 |
Why?
|
| Monocytes | 1 | 2014 | 2570 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 11121 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2011 | 1844 | 0.010 |
Why?
|
| Gene Expression | 1 | 2017 | 7581 | 0.010 |
Why?
|
| Sex Factors | 1 | 1998 | 10552 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 9280 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6484 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2015 | 3448 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 2385 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 20570 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 17635 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 8529 | 0.010 |
Why?
|
| Survivors | 1 | 2012 | 2371 | 0.010 |
Why?
|
| Prognosis | 1 | 2002 | 29625 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1998 | 9000 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2002 | 23995 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2008 | 1616 | 0.010 |
Why?
|
| Viral Load | 1 | 2010 | 3332 | 0.010 |
Why?
|
| Insulin | 2 | 2007 | 6596 | 0.010 |
Why?
|
| Hospitalization | 1 | 2020 | 10723 | 0.010 |
Why?
|
| Glucagon | 1 | 2002 | 532 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2002 | 1762 | 0.010 |
Why?
|
| Pregnancy | 1 | 2020 | 29874 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 8002 | 0.010 |
Why?
|
| Species Specificity | 1 | 2002 | 2414 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2010 | 3396 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2012 | 9318 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2010 | 2491 | 0.010 |
Why?
|
| HIV Infections | 1 | 2003 | 17351 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 58976 | 0.010 |
Why?
|
| Lung | 1 | 2014 | 10000 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 20098 | 0.010 |
Why?
|
| Cadaver | 1 | 1999 | 1358 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2014 | 54425 | 0.010 |
Why?
|